Dr  Reddy’s Laboratories has announced the launch of Obeda, its injectable Semaglutide, marking a significant milestone in expanding access to advanced GLP-1 receptor agonist therapies for the treatment of type 2 diabetes in India. The company claimed that it is the first Indian player to secure approval from the Drugs Controller General of India (DCGI) […]